AACR 2023 Poster 497

HX301, a First-in-class ARK5i, Demonstrates Antitumor Activity in Preclinical HCC Models with High ARK5/Myc Expression

Zhihua Jiao¹, Jessie Wang¹, Hang Ke², Faming Zhang², and Henry Li<sup>2

1</sup>Crown Bioscience, Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, USA
²Hanx Biopharmaceuticals, Ltd., Oceanside, California, US

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with few treatment options. Current drug therapies are often ineffective and toxic, and HCC has a poor prognosis. ARK5, a novel AMP-activated protein kinase family member 5, is overexpressed in many malignancies, including HCC, and is associated with poor prognosis and drug resistance. HX301 is a clinical stage first-in-class inhibitor of ARK5 and other kinase activities. In this study, HX301's antitumor activity was evaluated in HCC overexpressing both ARK5 and c-myc.

Download this Poster to Discover:

• The limitations of current drug therapies for HCC
  
  
• The role of ARK5 in HCC and its association with poor prognosis and drug resistance
  
  
• The potential of HX301 as a first-in-class ARK5 inhibitor for the treatment of advanced HCC with high expression of c-myc.

Download the Poster Now!